Aptevo Therapeutics Inc (APVO)

$4.55 -0.03 (-0.66%)
Market Cap 5.67M
Revenue (ttm) 0.00
Net Income (ttm) -25.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,800
Avg Vol 33,472
Day's Range N/A - N/A
Shares Out 1.25M
Stochastic %K 12%
Beta 1.68
Analysts Strong Sell
Price Target $25.50

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 838 0500
Fax: 206 838 0503
Address:
2401 4th Avenue, Suite 1050, Seattle, United States
ZacksSCR
ZacksSCR Jun. 25 at 3:51 PM
$APVO Lead candidate mipletamig posted an 87% clinical benefit rate in frontline AML, with no CRS reported through Cohort 5 of the RAINIER study. Pipeline also includes a new radiopharma collaboration w/ Niowave #AML #ImmunoOncology #Biotech https://youtu.be/xSbpWnpUI2c
1 · Reply
Quagglerock
Quagglerock Jun. 16 at 9:28 PM
$APVO New analyst rating with a fairly conservative treatment of pipeline with zero value on anything other than Mipletamig and 527. Both of those have high discount rates with low odds of approval. Even still, the DCF valuation is $30/share WITH 5x expected dilution. So we’re currently trading at only 15% of the extremely conservative valuation that factors in a bunch of negative stuff that hasn’t even happened. I don’t get it.
0 · Reply
ZacksSCR
ZacksSCR Jun. 16 at 1:17 PM
$APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement https://buff.ly/JVtvtJV
0 · Reply
Quagglerock
Quagglerock Jun. 14 at 9:32 PM
$APVO What happened to APV 527 in partnership with Alligator?
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 14 at 3:19 PM
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category | Nasdaq $APVO $RADX $AKTS https://www.nasdaq.com/press-release/big-pharma-bets-radiopharmaceuticals-aptevo-and-niowave-join-forces-advance-novel
0 · Reply
Quagglerock
Quagglerock Jun. 11 at 5:24 PM
$APVO Honestly have no idea what to think about Aptevo. The current market cap is outrageously low by all measures. Under $6 million with a full immuno platform with the lead asset producing data that reveals efficacy and safety that exceeds SOC in a large cancer arena. So confused. Should be at least 40-50x the current market cap. Why has a hostile not happened at this level?
0 · Reply
Quagglerock
Quagglerock Jun. 8 at 11:48 PM
$APVO Let me get this straight. They now have 8 drugs in development and just signed an agreement to start 3 new Radiopharmaceutical Programs? How on earth does a tiny team of this size move 11 assets forward? And this is all during a time where you supposedly have a marquee asset that is performing fantastically with growing data. What’s the end game here? The scientific immuno platform is stellar, but don’t you have to get something out the door? Or are they just building a sandbox for someone else to play in?
0 · Reply
Quagglerock
Quagglerock Jun. 7 at 5:02 PM
$APVO I’ve been here for years and have seen the ongoing dilution and RS cycle. But here we sit with an advancing set of oncology assets and entire platform that are continuing to exceed current SOC. Isn’t there an extreme disconnect from fundamental value (without the emotional baggage of the past) and the current market cap? There are many companies that have one asset that is less advanced with a market cap over $200 million and here we sit under $6 million. At what point does this get even slightly revalued?
0 · Reply
Jpeel1972
Jpeel1972 Jun. 3 at 9:21 PM
$APVO today was a pump and dump dilution day
0 · Reply
Ghostalini
Ghostalini Jun. 3 at 2:43 PM
$APVO This should be double digits. Waiting game.
0 · Reply
Latest News on APVO
Aptevo Therapeutics appoints Janatpour as SVP, CSO

2026-05-28T12:44:12.000Z - 4 weeks ago

Aptevo Therapeutics appoints Janatpour as SVP, CSO

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.

May 28, 2026, 8:05 AM EDT - 4 weeks ago

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.

Aptevo, Niowave launch collab for radiopharmaceutical oncology programs

2026-05-27T14:16:22.000Z - 4 weeks ago

Aptevo, Niowave launch collab for radiopharmaceutical oncology programs

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

May 27, 2026, 8:05 AM EDT - 4 weeks ago

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing

Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

2026-05-13T16:25:54.000Z - 6 weeks ago

Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

May 13, 2026, 8:05 AM EDT - 6 weeks ago

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial

2026-05-07T06:10:49.000Z - 7 weeks ago

Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

May 6, 2026, 8:05 AM EDT - 7 weeks ago

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year

2026-03-26T12:20:47.000Z - 3 months ago

Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year

Aptevo Therapeutics sees cash runway into 4Q26

2026-03-26T12:20:19.000Z - 3 months ago

Aptevo Therapeutics sees cash runway into 4Q26

Aptevo Provides State of the Business Report and 2025 Financial Results

Mar 26, 2026, 8:05 AM EDT - 3 months ago

Aptevo Provides State of the Business Report and 2025 Financial Results

Aptevo to Participate in March 2026 Conferences

Mar 19, 2026, 8:05 AM EDT - 3 months ago

Aptevo to Participate in March 2026 Conferences

Aptevo Therapeutics announces interim data for mipletamig combination

2026-03-10T12:45:45.000Z - 3 months ago

Aptevo Therapeutics announces interim data for mipletamig combination

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Mar 10, 2026, 8:05 AM EDT - 3 months ago

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Aptevo Therapeutics CEO Marvin White to retire, assume Executive Chair role

2026-02-03T13:50:44.000Z - 5 months ago

Aptevo Therapeutics CEO Marvin White to retire, assume Executive Chair role

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Feb 3, 2026, 8:05 AM EST - 5 months ago

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Aptevo Therapeutics files to sell 7.075M shares of common stock for holders

2026-01-28T21:11:23.000Z - 5 months ago

Aptevo Therapeutics files to sell 7.075M shares of common stock for holders

Aptevo Therapeutics secures $60M equity line of credit

2026-01-09T13:21:26.000Z - 6 months ago

Aptevo Therapeutics secures $60M equity line of credit

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Jan 9, 2026, 8:05 AM EST - 6 months ago

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Aptevo Therapeutics trading halted, news pending

2025-12-30T00:50:33.000Z - 6 months ago

Aptevo Therapeutics trading halted, news pending

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

Dec 26, 2025, 8:05 AM EST - 6 months ago

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

Aptevo Therapeutics presents preliminary results from Phase 1b/2 RAINIER study

2025-12-09T13:26:08.000Z - 7 months ago

Aptevo Therapeutics presents preliminary results from Phase 1b/2 RAINIER study

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Dec 9, 2025, 8:05 AM EST - 7 months ago

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Aptevo Therapeutics debuts trispecific antibody candidate APVO451

2025-11-10T14:16:00.000Z - 8 months ago

Aptevo Therapeutics debuts trispecific antibody candidate APVO451

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Nov 10, 2025, 8:05 AM EST - 8 months ago

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Aptevo Therapeutics management to meet virtually with Roth Capital

2025-11-06T18:25:23.000Z - 8 months ago

Aptevo Therapeutics management to meet virtually with Roth Capital

Aptevo Therapeutics reports Q3 EPS ($2.23) vs. ($357.86) last year

2025-11-06T14:21:24.000Z - 8 months ago

Aptevo Therapeutics reports Q3 EPS ($2.23) vs. ($357.86) last year

Aptevo Therapeutics sees cash runway into 4Q26

2025-11-06T14:21:03.000Z - 8 months ago

Aptevo Therapeutics sees cash runway into 4Q26

Aptevo Therapeutics reports Q3 EPS (23c) vs. ($357.86) last year

2025-11-06T14:15:21.000Z - 8 months ago

Aptevo Therapeutics reports Q3 EPS (23c) vs. ($357.86) last year

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Nov 6, 2025, 8:05 AM EST - 8 months ago

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Oct 8, 2025, 8:20 AM EDT - 9 months ago

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Aptevo Therapeutics files to sell 6.9M shares of common stock for holders

2025-10-01T20:35:07.000Z - 9 months ago

Aptevo Therapeutics files to sell 6.9M shares of common stock for holders

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 16, 2025, 8:30 AM EDT - 10 months ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Sep 4, 2025, 8:45 AM EDT - 10 months ago

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 13, 2025, 8:05 AM EDT - 11 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aug 11, 2025, 8:05 AM EDT - 11 months ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 11:30 AM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:55 AM EDT - 1 year ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 1:34 PM EDT - 1 year ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 10:52 AM EDT - 1 year ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 18, 2025, 8:01 AM EDT - 1 year ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Aptevo Participating in the BIO International Convention

Jun 13, 2025, 8:05 AM EDT - 1 year ago

Aptevo Participating in the BIO International Convention

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 22, 2025, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 15, 2025, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

May 8, 2025, 8:45 AM EDT - 1 year ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 1 year ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 1 year ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 20, 2025, 8:35 AM EDT - 1 year ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 18, 2025, 8:05 AM EDT - 1 year ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Aptevo to Participate in March Conferences

Mar 6, 2025, 8:00 AM EST - 1 year ago

Aptevo to Participate in March Conferences

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 15, 2025, 6:59 PM EST - 1 year ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Feb 14, 2025, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Jan 15, 2025, 8:00 AM EST - 1 year ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 12:50 PM EST - 1 year ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 12, 2024, 9:00 AM EST - 1 year ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Dec 4, 2024, 8:35 AM EST - 1 year ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 29, 2024, 9:55 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 26, 2024, 8:35 AM EST - 1 year ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 22, 2024, 8:35 AM EST - 1 year ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 20, 2024, 8:35 AM EST - 1 year ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 11, 2024, 8:15 AM EST - 1 year ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Nov 7, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 13, 2024, 8:05 AM EDT - 2 years ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Aug 8, 2024, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

ZacksSCR
ZacksSCR Jun. 25 at 3:51 PM
$APVO Lead candidate mipletamig posted an 87% clinical benefit rate in frontline AML, with no CRS reported through Cohort 5 of the RAINIER study. Pipeline also includes a new radiopharma collaboration w/ Niowave #AML #ImmunoOncology #Biotech https://youtu.be/xSbpWnpUI2c
1 · Reply
Quagglerock
Quagglerock Jun. 16 at 9:28 PM
$APVO New analyst rating with a fairly conservative treatment of pipeline with zero value on anything other than Mipletamig and 527. Both of those have high discount rates with low odds of approval. Even still, the DCF valuation is $30/share WITH 5x expected dilution. So we’re currently trading at only 15% of the extremely conservative valuation that factors in a bunch of negative stuff that hasn’t even happened. I don’t get it.
0 · Reply
ZacksSCR
ZacksSCR Jun. 16 at 1:17 PM
$APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement https://buff.ly/JVtvtJV
0 · Reply
Quagglerock
Quagglerock Jun. 14 at 9:32 PM
$APVO What happened to APV 527 in partnership with Alligator?
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 14 at 3:19 PM
As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category | Nasdaq $APVO $RADX $AKTS https://www.nasdaq.com/press-release/big-pharma-bets-radiopharmaceuticals-aptevo-and-niowave-join-forces-advance-novel
0 · Reply
Quagglerock
Quagglerock Jun. 11 at 5:24 PM
$APVO Honestly have no idea what to think about Aptevo. The current market cap is outrageously low by all measures. Under $6 million with a full immuno platform with the lead asset producing data that reveals efficacy and safety that exceeds SOC in a large cancer arena. So confused. Should be at least 40-50x the current market cap. Why has a hostile not happened at this level?
0 · Reply
Quagglerock
Quagglerock Jun. 8 at 11:48 PM
$APVO Let me get this straight. They now have 8 drugs in development and just signed an agreement to start 3 new Radiopharmaceutical Programs? How on earth does a tiny team of this size move 11 assets forward? And this is all during a time where you supposedly have a marquee asset that is performing fantastically with growing data. What’s the end game here? The scientific immuno platform is stellar, but don’t you have to get something out the door? Or are they just building a sandbox for someone else to play in?
0 · Reply
Quagglerock
Quagglerock Jun. 7 at 5:02 PM
$APVO I’ve been here for years and have seen the ongoing dilution and RS cycle. But here we sit with an advancing set of oncology assets and entire platform that are continuing to exceed current SOC. Isn’t there an extreme disconnect from fundamental value (without the emotional baggage of the past) and the current market cap? There are many companies that have one asset that is less advanced with a market cap over $200 million and here we sit under $6 million. At what point does this get even slightly revalued?
0 · Reply
Jpeel1972
Jpeel1972 Jun. 3 at 9:21 PM
$APVO today was a pump and dump dilution day
0 · Reply
Ghostalini
Ghostalini Jun. 3 at 2:43 PM
$APVO This should be double digits. Waiting game.
0 · Reply
kimesther
kimesther Jun. 3 at 2:17 PM
$APVO 뒤져라 시발년들
0 · Reply
Marcel20
Marcel20 Jun. 3 at 6:26 AM
$APVO naja
0 · Reply
Marcel20
Marcel20 Jun. 3 at 5:10 AM
$APVO boom soon🔥???
0 · Reply
BillionaireMotion
BillionaireMotion May. 29 at 5:59 PM
$ATCH $LASE $APVO BB
0 · Reply
PatentGrants
PatentGrants May. 27 at 7:56 PM
$APVO Aptevo Therapeutics has received a Notice of Allowance for a US patent titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)". https://patentcenter.uspto.gov/applications/16871597/ifw/docs
0 · Reply
prismmarketview
prismmarketview May. 27 at 5:16 PM
$APVO teaming up with Niowave in a 50/50 collab to develop up to 3 radiopharmaceutical oncology programs. Niowave now owns 7.9% of $APVO with warrants to go up to ~20%. #APVO #Biotech #Oncology #Radiopharma #MicroCap https://prismmarketview.com/radiopharma-push-aptevo-and-niowave-join-forces-in-oncology/
0 · Reply
Stock_Catcher
Stock_Catcher May. 27 at 12:19 PM
$APVO Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
0 · Reply
BillionaireMotion
BillionaireMotion May. 21 at 9:20 PM
$APVO $PBM $RAYA Have you missed the recent 800%+ runners?! Make sure to keep ticker EZRA on watch ! Taking a position at these levels. I really hope the shorts get squeezed out hard. EZRA has barely 530k shares outstanding. We saw a mini spike pre-market earlier.. Would not be surprised if it runs wild soon. The key is to buy before the crowd 💎
0 · Reply
theBigDollarski
theBigDollarski May. 21 at 3:33 PM
$APVO another day....another check for Marvin....
0 · Reply
gATERaids
gATERaids May. 19 at 4:05 PM
$ATER That stock $APVO which this guy @SEC_LIARS also said would be $1 is now over $4, which proves exactly why nobody should take note of this paid FUD spreader.
0 · Reply
IUPwiggum
IUPwiggum May. 15 at 7:09 PM
$APVO are we done with the reverse splits here?
1 · Reply